Common Contracts
2 similar First Supplemental Indenture contracts by Intercept Pharmaceuticals Inc, Intrexon Corp
INTREXON CORPORATION AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of July 3, 2018 3.50% Convertible Senior Notes due 2023First Supplemental Indenture • July 3rd, 2018 • Intrexon Corp • Services-commercial physical & biological research • New York
FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”) dated as of July 3, 2018 between INTREXON CORPORATION, a Virginia corporation, as issuer (the “Issuer,” as more fully set forth in Section 1.02) and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.02).
INTERCEPT PHARMACEUTICALS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of July 6, 2016 to Indenture for Senior Debt Securities Dated as of July 6, 2016 3.25% Convertible Senior Notes due 2023First Supplemental Indenture • July 6th, 2016 • Intercept Pharmaceuticals Inc • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE dated as of July 6, 2016 (this “Supplemental Indenture”) between INTERCEPT PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Issuer,” as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01), supplementing the Indenture for Senior Debt Securities dated as of July 6, 2016 between the Issuer and the Trustee (the “Base Indenture” and the Base Indenture, as amended and supplemented by this Supplemental Indenture, and as it may be further amended or supplemented from time to time with respect to the Notes, the “Indenture”).
